Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13660
Title: | RNA Interference Nanotherapeutics for Treatment of Glioblastoma Multiforme |
Authors: | Chitkara, Deepak Mittal, Anupama |
Keywords: | Pharmacy Glioblastoma multiforme Nucleic acid therapeutics Molecular pathways Nanocarriers siRNA miRNAs |
Issue Date: | Sep-2020 |
Publisher: | ACS |
Abstract: | Nucleic acid therapeutics for RNA interference (RNAi) are gaining attention in the treatment and management of several kinds of the so-called “undruggable” tumors via targeting specific molecular pathways or oncogenes. Synthetic ribonucleic acid (RNAs) oligonucleotides like siRNA, miRNA, shRNA, and lncRNA have shown potential as novel therapeutics. However, the delivery of such oligonucleotides is significantly hampered by their physiochemical (such as hydrophilicity, negative charge, and instability) and biopharmaceutical features (in vivo serum stability, fast renal clearance, interaction with extracellular proteins, and hindrance in cellular internalization) that markedly reduce their biological activity. Recently, several nanocarriers have evolved as suitable non-viral vectors for oligonucleotide delivery, which are known to either complex or conjugate with these oligonucleotides efficiently and also overcome the extracellular and intracellular barriers, thereby allowing access to the tumoral micro-environment for the better and desired outcome in glioblastoma multiforme (GBM). This Review focuses on the up-to-date advancements in the field of RNAi nanotherapeutics utilized for GBM treatment. |
URI: | https://pubs.acs.org/doi/full/10.1021/acs.molpharmaceut.0c00709 http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13660 |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.